Introduction
A recent meta-analysis estimated worldwide human papillomavirus (HPV) prevalence among women at 10.4 . HPV genotypes
are divided into high-risk and low-risk genotypes, on the basis of their association with cervical lesions. The high-risk human
papillomavirus (HR-HPV) types are more frequently found in pre-malignant or malignant lesions and are associated with cancers of the cervix, vulva, vagina, anus, and penis . A causal association between cervical cancer and HR-HPV has now been established and worldwide HR-HPV prevalence of cervical carcinomas has been estimated at 99.7 . Cervical cancer is the most common cancer % [10 ] affecting women in developing countries, with over 70 of cases occurring in Africa being attributed to HR-HPV genotypes 16 and 18 ,
. Thus, any factor reducing the probability of acquiring or transmitting HPV will also considerably reduce the burden of disease, 11 12 ] especially in the developing world .
[4 ]
Observational studies have suggested that HPV prevalence is reduced among circumcised men compared with uncircumcised men , [3 , . Nevertheless, such an association has not yet been proven using a randomized controlled trial (RCT). The objective of this 4 13 -15 ] study was to analyze the effect of male circumcision (MC) on HR-HPV prevalence using data collected during a male circumcision RCT conducted in Orange Farm (South Africa), which demonstrated a partial protective effect of MC on the acquisition of HIV by young males.
Methods

Collection of data
The technical details of the trial (ANRS-1265) have been published elsewhere and only a summary will be presented in this [16 ] article. anatomical site is probably not affected by circumcision status. These swabs were analyzed to assess the association between the prevalence of HR-HPV strains and male circumcision. A urethral swab was also collected at a follow-up visit about 6 weeks after MC from all control group participants who took part in a nested study designed to compare two circumcision methods. To ascertain that the detection of HR-HPV was not affected by circumcision status, we used these swabs to compare the prevalence of HR-HPV among the nested study participants before and after circumcision. Lastly, study participants were asked to give a first-void urine sample in order to test for urogenital (NG), which presence was used as a biological marker of sexual behavior. Neisseria gonorrhea
Laboratory methods
Specimens were frozen at 20 C immediately after collection and kept frozen until processing. DNA was extracted from the urethral internal beta globin PCR control were excluded. All positives were genotyped. An HPV-positive sample was defined by a sample where at least one HR-HPV was detected. In some analyses we also considered multiple HPV samples defined for samples where at least two HR-HPV genotypes were detected. Urine specimens were tested for NG by PCR (Roche Cobas Amplicor PCR).
Data analysis
The intention-to-treat and as-treated prevalence rate ratios (PRRs) of HR-HPV-positivity and NG-positivity were estimated using univariate log-Poisson regression These analyses were repeated multivariately by controlling for ethnic group, age, education, number of lifetime partners, marital status, number of non-spousal partners in the past 12 months, condom use in the past 12 months, number of sex acts in the past 12 months and HIV status.
To assess the potential impact of HIV acquisition, which is reduced by MC and is associated with HPV infection , these analyses [17 ] were repeated after excluding those who seroconverted for HIV during the follow-up period (n 25).
=
To evaluate a possible imbalance between the groups, analyses were repeated when controlling for propensity score coded in quintiles . [18 ] Statistical analyses were performed using the statistical package SPSS for Windows version 8 (SPSS, Chicago, Illinois, United States) and R programming language (version 2.6.1) .
[19 ]
Ethics
The research protocol was reviewed and approved by 
Results
Baseline characteristics of the 1264 participants from whom a urethral swab was collected at the 21-month visit are reported by randomization group in . These characteristics are similar and not statistically different except for HIV status. The mean (median) Table 1 duration in days of follow-up among the intervention and control group was 644 (637) vs. 649 (637), respectively. presents the intention-to-treat univariate association between HR-HPV prevalence and male circumcision at the scheduled Table 2 21-month visit. HR-HPV prevalence was significantly lower among men of the intervention group. As indicated in , the Figure 1 percentage of each of the 13 HR-HPV genotypes was always lower among men of the intervention group than among men of the control group. In the intention-to-treat comparison, the difference was significant for genotypes 18, 31, 45, 52, 56, 58, and 68.
shows that the protective effect of MC on HR-HPV is higher in the as-treated analysis than in the intention-to-treat analysis. Table 2 The protective effect is also higher in both analyses when controlling for potential confounders, including HIV status and reported sexual behavior cofactors. HR-HPV was associated with HIV status in both analyses with aPRRs of 2.2 (95 CI 1.5 3.3) and 2.2 (95 CI 1.5 % -% -3.2), respectively. When those who seroconverted for HIV during follow-up were excluded from the analysis, the results indicated in Table   remained practically unchanged with -values less than 0.009 and a relative variation of the PRRs and aPRRs of less than 5.2 . This 2 P % suggests that the effect of MC on HR-HPV is independent of the effect of MC on HIV. The aPRRs were almost identical when the analyses were adjusted for the propensity score in addition to the other covariates.
Multiple HR-HPV prevalence was 7.0 (89/1267; 95 CI: 5.7 8.6 ). It was significantly lower among men of the intervention 
0.94; 0.020).
As indicated in , NG prevalence was similar in the two groups. Among men of the control and intervention groups, median Table 3 number of lifetime partners was 4.1 and 4.2, respectively, ( 0.49; Kruskal-Wallis test) and the proportion of consistent condom users P = was 17.4 and 19.7 , respectively, ( 0.45; Fisher exact test). These findings suggest that the protective effect of MC on HR-HPV % % P = cannot be attributed to a difference of sexual behavior between the two groups.
During the study period, 371 men of the control group were circumcised and had a urethral swab taken before and after male circumcision. The average (median) duration between the two swab collections was 59 (43) days. As expected, the HR-HPV prevalence was the same between the two samplings (23.7 vs. 23.9 ; 1.0; Sign test). The proportion of males with multiple HR-HPV genotype % % P = infections was not significantly different (10.2 vs. 12.1 ; 0.40; Sign test). These results indicate that the as-treated effect of male % % P = circumcision on HR-HPV prevalence shown in cannot be attributed to an easier detection of HR-HPV by urethral swabbing in Table 2 uncircumcised men compared with circumcised men.
Discussion
Using data collected during the MC trial conducted in Orange Farm (South Africa), we demonstrated an independent and partial protective effect of male circumcision on HR-HPV prevalence. The effect was shown on HR-HPV prevalence and not incidence due to the available biological samples in this MC trial. This effect remained unchanged when the analysis was adjusted for possible confounding factors such as sexual behavior and condom use. Due to a) the randomization, b) the results of the propensity analysis, and c) the absence of obvious differences in the gonorrheal prevalence and sexual behavioral characteristics between the intervention and control groups, the HR-HPV prevalence difference between the two groups is likely attributable to male circumcision. In this view, the difference observed is probably the consequence of a difference in HR-HPV incidence between circumcised and uncircumcised men. Indeed, in this study HR-HPV prevalence is likely a proxy for HR-HPV incidence because among young men HPV prevalence is rising as a function of age [20 . ] This study has some limitations. Biological samples were not collected throughout the follow-up period, so the HR-HPV status at inclusion is unknown. This information would have allowed us to compare HR-HPV incidence as a function of MC status and HR-HPV prevalence between intervention groups at inclusion. Because some participants were certainly already infected by HR-HPV at inclusion, the effect measured on prevalence is an underestimation of the true effect of MC. Secondly, the fact that participants were not blind to the intervention could have led to sexual behavior change and bias. Lastly, HR-HPV detection was performed on urethral swabs which are likely to miss infections . Thus, the prevalence of HR-HPV infections in our cohort is likely to be underestimated since detection in [21 ] the urethra is significantly lower than detection in the glans, corona sulcus or the penis shaft , . However, we believe that there is no [21 22 ] risk of non-differential misclassification since we did not find any difference when we compared the urethral HR-HPV prevalences before and after circumcision among a sub-sample of participants. Hence we believe that HR-HPV infections will be underestimated equally among the two arms and will have no effect on PRRs. Despite this loss of power, our study evidenced a significant protective effect of MC against HPV infection. the effect of MC according to genotype can be due to a true variation of the effect of MC according to genotypes or to random variation. This possible variation of the effect of MC according to genotypes should be further investigated for example by combining the results of this study with the results of the other MC trials conducted in Kenya and Uganda , . [ circumcision decreases the heterosexual risk of HR-HPV acquisition by males.
HR-HPV is a major public health problem because of its causal association with malignancies, especially cervical cancer in women.
Hence this study illustrates why MC has long been thought to be protective against cervical cancer . Indeed, as shown in our study, MC
Figure 1
Distribution of the high-risk HPV genotypes as a function of randomization group. 
